ANI Pharmaceuticals (NASDAQ:ANIP) Upgraded at StockNews.com

StockNews.com upgraded shares of ANI Pharmaceuticals (NASDAQ:ANIP) from a sell rating to a hold rating in a research note issued to investors on Friday.

Other research analysts also recently issued research reports about the stock. Leerink Partnrs raised shares of ANI Pharmaceuticals to a “strong-buy” rating in a research note on Wednesday, December 11th. Jefferies Financial Group began coverage on shares of ANI Pharmaceuticals in a research note on Friday. They issued a “buy” rating and a $80.00 target price for the company. JPMorgan Chase & Co. began coverage on shares of ANI Pharmaceuticals in a research note on Wednesday, March 12th. They issued an “overweight” rating and a $85.00 target price for the company. Guggenheim upped their price objective on shares of ANI Pharmaceuticals from $84.00 to $86.00 and gave the company a “buy” rating in a research note on Wednesday, March 5th. Finally, HC Wainwright reaffirmed a “buy” rating and set a $94.00 price objective on shares of ANI Pharmaceuticals in a research note on Monday, March 3rd. Two analysts have rated the stock with a hold rating, seven have given a buy rating and one has assigned a strong buy rating to the company. According to MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and an average target price of $79.75.

ANI Pharmaceuticals Trading Up 1.7 %

Shares of ANIP stock opened at $62.49 on Friday. The firm has a 50-day moving average price of $58.40 and a 200 day moving average price of $58.06. ANI Pharmaceuticals has a twelve month low of $52.50 and a twelve month high of $70.81. The company has a market capitalization of $1.36 billion, a price-to-earnings ratio of -113.62 and a beta of 0.62. The company has a current ratio of 2.74, a quick ratio of 1.97 and a debt-to-equity ratio of 1.52.

Insider Transactions at ANI Pharmaceuticals

In other news, CFO Stephen P. Carey sold 7,500 shares of the business’s stock in a transaction dated Tuesday, December 17th. The stock was sold at an average price of $55.79, for a total transaction of $418,425.00. Following the completion of the sale, the chief financial officer now owns 154,468 shares in the company, valued at approximately $8,617,769.72. The trade was a 4.63 % decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Also, VP Meredith Cook sold 400 shares of the business’s stock in a transaction dated Thursday, March 13th. The stock was sold at an average price of $63.33, for a total value of $25,332.00. Following the sale, the vice president now owns 80,545 shares of the company’s stock, valued at $5,100,914.85. The trade was a 0.49 % decrease in their position. The disclosure for this sale can be found here. In the last quarter, insiders sold 10,700 shares of company stock worth $610,201. 12.70% of the stock is currently owned by company insiders.

Institutional Trading of ANI Pharmaceuticals

Institutional investors have recently modified their holdings of the company. Principal Financial Group Inc. boosted its holdings in ANI Pharmaceuticals by 6.9% in the 3rd quarter. Principal Financial Group Inc. now owns 89,961 shares of the specialty pharmaceutical company’s stock worth $5,367,000 after acquiring an additional 5,829 shares during the period. Victory Capital Management Inc. boosted its holdings in ANI Pharmaceuticals by 153.6% in the 3rd quarter. Victory Capital Management Inc. now owns 12,919 shares of the specialty pharmaceutical company’s stock worth $771,000 after acquiring an additional 7,825 shares during the period. Mizuho Markets Americas LLC purchased a new position in ANI Pharmaceuticals in the 3rd quarter worth approximately $11,670,000. Natixis Advisors LLC boosted its holdings in ANI Pharmaceuticals by 56.2% in the 3rd quarter. Natixis Advisors LLC now owns 18,184 shares of the specialty pharmaceutical company’s stock worth $1,085,000 after acquiring an additional 6,545 shares during the period. Finally, Thrivent Financial for Lutherans boosted its holdings in ANI Pharmaceuticals by 2.3% in the 3rd quarter. Thrivent Financial for Lutherans now owns 13,028 shares of the specialty pharmaceutical company’s stock worth $777,000 after acquiring an additional 299 shares during the period. Hedge funds and other institutional investors own 76.05% of the company’s stock.

ANI Pharmaceuticals Company Profile

ANI Pharmaceuticals, Inc, a biopharmaceutical company, develops, manufactures, and markets branded and generic prescription pharmaceuticals in the United States and Canada. The company manufactures oral solid dose products; semi-solids, liquids, and topicals; controlled substances; and potent products, as well as performs contract development and manufacturing of pharmaceutical products.